Why it's time to buy ResMed Inc. (CHESS) and Cochlear Limited shares

Cochlear Limited (ASX:COH) and ResMed Inc. (CHESS) (ASX:RMD) look a buy today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Along with the broader S&P/ASX 200 (Index: ^AXJO) (ASX: XJO), shares of ResMed Inc. (CHESS) (ASX: RMD) and Cochlear Limited (ASX: COH) today fell following disappointing economic data out of China yesterday.

However, long-term investors should relish down days like today, by using the opportunity to buy more shares in quality businesses at cheaper prices. ResMed Inc. and Cochlear are two such quality businesses.

Why?

Over the past 10 years, ResMed's ASX-listed shares have achieved an average annual total shareholder return (dividends plus capital gains) of 11.5%. ResMed is a global biotechnology business specialising in the development of products for the treatment of sleep apnea and related respiratory disorders.

Being a global leader in biotechnology, ResMed generates wide profit margins and large amounts of recurring revenue, but it also earns its profit in US dollars. Therefore, further downward movements in the Australian dollar provide a currency kicker for ResMed shareholders. Falling almost 2% today, investors could use the recent share price weakness to top up on ResMed shares.

Cochlear is also globally diversified. The company is an international leader in the design, development and manufacture of devices for use by hearing loss sufferers. The Cochlear brand has been in use for decades, yet its best days could lay ahead.

Indeed, analysts are forecasting strong profit and dividend increases over the next three years. With a 2.2% fully franked dividend yield to boot, savvy long-term investors could do worse than add Cochlear shares to their portfolio following today's 2.16% fall.

Foolish takeaway

If you're seeking recurring revenue, overseas exposure, dividends and long-term growth, both Cochlear and ResMed shares are a buy, in my opinion. Indeed, while short-term weakness could persist, the longer-term outlook for both businesses is increasingly bright.

Motley Fool writer/analyst Owen Raszkiewicz owns shares of Cochlear and ResMed. Owen welcomes your feedback on Google plus (see below), LinkedIn or you can follow him on Twitter @ASXinvest. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »